JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
85 hedge funds and large institutions have $176M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
16% less capital invested
Capital invested by funds: $210M → $176M (-$34.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Holders
85
Holding in Top 10
3
Calls
$3.94M
Puts
$543K
Top Buyers
| 1 | +$1.73M | |
| 2 | +$1.32M | |
| 3 | +$1.3M | |
| 4 |
Renaissance Technologies
New York
|
+$1.09M |
| 5 |
Two Sigma Advisers
New York
|
+$840K |
Top Sellers
| 1 | -$5.13M | |
| 2 | -$4.8M | |
| 3 | -$2.24M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.05M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$766K |